Naval Daver, MD, explains the progress made on 3 abstracts he’s involved with regarding acute myeloid leukemia (AML) at the ASH Annual Meeting and Exposition.
Courtney DiNardo, MD, MSCE, elaborated on interim phase II results regarding enasibenib plus azacitidine in patients with newly diagnosed acute myeloid leukemia, and the results from the QUAZAR trial.
Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.
The Willamette Valley Cancer Institute and Research Center expert talks about the results of the ELEVATE TN trial at the ASH Annual Meeting and Exposition.
The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition.
The expert hematologist from Plymouth University Medical Center discussed the long-term outcomes of patients receiving ibrutinib for mantle cell lymphoma at the ASH Annual Meeting and Exposition.
Bijal D. Shah, MD, discusses the progress made regarding CAR T-cell therapy and mantle cell lymphoma.
The Mayo Clinic expert highlights exciting advancements being made in chimeric antigen receptor T-cell therapy for blood cancer.
The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.
The Memorial Sloan Kettering Cancer Center expert discussed a study he designed to discover why and how melanoma metastasizes, at the 16th International Congress of the Society for Melanoma Research.